← FDA DRUG APPROVALS

FDA NDA · NDA215429

VENLAFAXINE

Sponsor: ALMATICA

APPLICATION
NDA215429
TYPE
NDA
ORIGINAL APPROVAL
2022-06-29
LATEST ACTION
2023-08-18
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

VENLAFAXINE BESYLATE · ReferencePrescription
VENLAFAXINE BESYLATE EQ 112.5MG BASE · TABLET, EXTENDED RELEASE · ORAL

Approval history

2023-08-18Labeling · Supplement 1 · standard — Label ↗AP
2022-06-29Type 2 - New Active Ingredient and Type 3 - New Dosage Form · Original · standard — Letter ↗AP
2022-06-29Type 2 - New Active Ingredient and Type 3 - New Dosage Form · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →